Scientific Presentations

Chronic Lung Allograft Dysfunction (CLAD), the leading cause for re-transplantation associated with high cost

Trend in lung transplantation in Europe 2015 – 2019, type of transplant and organ source

Survival after lung transplantation in Europe – CLAD as major cause of death

Study design of two Phase III, prospective, multicenter, randomized, controlled clinical trials evaluating the efficacy and safety of Liposomal Cyclosporin A for Inhalation (L-CsA-i) in patients with Bronchiolitis Obliterans Syndrome post single- (BOSTON-1) or double- (BOSTON-2) lung transplantation

Development in lung transplantation, organ shortage, Bronchiolitis Obliterans and overall survival in the US, 2011 -2018

Ensuring Patient Safety And Data Integrity In Clinical Trials for The Treatment Of Bronchiolitis Obliterans Syndrome (BOS) During The COVID-19 Pandemic

Bronchiolitis Obliterans Syndrome after Lung Transplantation: Economic Burden

Lung function monitoring in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients

Use Of Functional Respiratory Imaging (FRI) To Explore Drug Delivery And Lung Deposition Of Inhaled Liposomal Cyclosporine A (L-CsA-i) In Patients After Lung Transplantation

Pediatric Patients with Bronchiolitis Obliterans Syndrome (BOS): Dosing and Breath Simulation Experiments of Liposomal Cyclosporin A for Inhalation (L-CsA-i)

Prevalence of Bronchiolitis Obliterans Syndrome Following Allogeneic Haematopoietic Stem Cell Transplant in the United States, Europe, and Japan

The Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation Patients with Medicare Coverage

The Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) in Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Patients with Medicare Coverage

Real World Trends in Monitoring Lung Transplant Recipients for Lung Allograft Dysfunction

Economic Burden of Bronchiolitis Obliterans Syndrome (BOS) Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients with Commercial Insurance in the United States

The clinical, humanistic and economic burden of bronchiolitis obliterans syndrome in Europe

A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation

Liposomal Cyclosporine A for Inhalation (L-CsA-i): Innovation in the Treatment of Bronchiolitis Obliterans Syndrome (BOS)

ISHLT Registry Data and Country Registries: Comparison of Reported European/Israeli Lung Transplant Activities in 2016

L-CsA-i, a Liposomal Formulation of Cyclosporine, Demonstrates Therapeutic Potential for Bronchiolitis Obliterans Syndrome (BOS)

Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability

Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome (BOS): Novel Formulation With Therapeutic Potential for Patients With BOS Following allo-HSCT